Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer

Journal of the Formosan Medical Association

Volumn 102, Issue 12, 2003, Pages 857-862

  Yang, Kuo Ching ^a   Wang, Gen Ming ^a   Chen, Jui Hao ^a   Chen, Tong Jong ^a   Lee, Shui Cheng ^b  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

Anti ulcer agents; Helicobacter pylori; Omeprazole; Peptic ulcer

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; UREA;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; CAMPYLOBACTER; CHOLESTEATOMA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EAR SURGERY; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PARANASAL SINUSITIS; PATIENT COMPLIANCE; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TREATMENT OUTCOME; ULCER HEALING; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PEPTIC ULCER; TREATMENT OUTCOME;

EID: 2342644936     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Hunt RH, Lam SK: Helicobacter pylori: from art to a science. J Gastroenterol Hepatol 1998;13:21-8.
2. Walsh JH, Peterson WL: The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995;333:984-91.
3. Hopkins RJ, Girardi LS, Turney EA: Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996;110: 1244-52.
4. Lam SK, Talley NJ: Report of the 1997 Asia Pacific Consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12.
5. Malfertheiner P, Megraud F, O'Morain, et al: Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16;167-80.
6. Calabrese C, Di Febo G, Areni A, et al: Pantoprazole, azithromycin and tinidazole: short duration triple therapy for eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14: 1613-7.
7. Hurenkamp GJ, Van Der Ende A, Grudmeijer HG, et al: Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer diseases. Aliment Pharmacol Ther 2000;14:1065-70.
8. O'Connor HJ, McLoughlin R, Kelly S, et al: Lansoprazole triple therapy for Helicobacter pylori - is 5 days enough? Aliment Pharmacol Ther 1998;12:273-6.
9. Neville PM, Everett S, Langworthy H, et al: The optimal antibiotic combination in a 5-day Helibacter pylori eradication regimen. Aliment Pharmacol Ther 1999;13:497-501.
10. Catalano F, Catanzaro R, Branciforte G, et al: Five-day triple therapy in Helicobacter pylori-positive duodenal ulcer: an eighteen-month follow-up. J Clin Gastroenterol 2000;31:130-6.
11. Peterson WL. The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997;11 (Suppl.):S21-5.
12. Lind T, Megraud F, Unge P, et al: The MACH 2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116:248-53.
13. Williams MP, Pounder RE: Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999;13(Suppl 3):3-10.
14. Stedman CA, Barclay ML: Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000;14:963-78.
15. Wong BCY, Wong WM, Yee YK, et al: Rebeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2001;15:1959-65.
16. Wang YY, Hu LY, Wang GM, et al: Ideal media combination for primary isolation of Helicobacter pylori. J Biomed Lab Sci 1999; 11:176-8.
17. Huang AH, Sheu BS, Yang HB, et al: Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy. J Formos Med Assoc 2000; 99:704-9.
18. 13C-urea breath test. Gastroenterol J Taiwan 2000;17:252-6.
19. 13C] urea breath test is helpful to monitor H. pylori eradication after proton pump inhibitor-based triple therapy. Dig Dis Sci 2000;45:1330-6.
20. Catalano F, Branciforte G, Catanzaro R, et al: Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen. Aliment Pharmacol Ther 2000;14:1329-34.
21. Isomoto H, Furusu H, Morikawa T, et al: 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14:1619-23.
22. Calvet X, Garcia N, Lopez T, et al: A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:603-9.
23. Wang WH, Wong BC, Mukhopadhyay AK, et al: High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol Ther 2000;14;901-10.
24. Kawakami Y, Akahane T, Yamaguchi M, et al: In vitro activities of raveprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 2000;44:458-61.
25. Stack WA, Knifton A, Thirlwell D, et al: Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenterol 1998;93:1909-13.
26. Miwa H, Ohkura R, Murai T, et al: Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999;13:741-6.
27. Miwa H, Yamada T, Sato K, et al: Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. Dig Dis Sci 2000;45:77-82.